References to Primarv Literature
- SULZBERGER MB, WITTEN VH: The effect of topically applied compound F in selected dermatoses. J. Invest. Derrnatol. (1952) 19:101–102.
- ELKS J: Steroid structure and steroid activity. Br. J. Dermatol. (1976) 94\(Suppl. 12):3–13.
- CHU AC, MUNN S: Fluticasone propionate in the treat-ment of inflammatory dermatoses. Br.J. Clin. Pharmacol. (1995) 49:131–133.
- KAPLAN RP, RUSSELL DH, LOWE NJ: Etretinate treatmentfor psoriasis: clinical response, remission times, epi-dermal differentiation and polyamine response. J. Am. Acad. Dermatol. (1983) 8:95–107.
- CUNLEFFE WJ, JONES DH, PRITLOVE J, PARKIN D: Longterm benefit of isotretinoin in acne; clinical and labo-ratorfy studies. In: Retinoids: New Trends in Research and Therapy. Retinoid Symposium, Geneva (1985):247–251.
- KRAGBALLE K: Vitamin D3 analogues. Dermatol. OM. (1995) 13:835–839.
- KADUNCE DP, KRUEGER GG: Pathogenesis of psoriasis: current concepts. Dermatol. Clin (1995) 13:723–737.
- WAHLGREN CF, TENGVALL-LINDER M, HAGERMARK 0,SCHEYNIUS A: Itch and inflammation induced by intrad-ermally injected interleukin-2 in atopic dermatitis pa-tients and healthy subjects. Arch. Dermatol. Res. (1995) 287:572–580
- PRENS EP, VAN JOOST, HEGMANS JP et al: Effects ofcyclosporine and cytokine receptors in psoriasis. J. Am. Acad. Derrnatot (1995) 33:947–953
- LEMSTER BH, CARROLL PB, RILO HR et al.: IL-8/IL-8receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin. Exp. Immu-nol. (1995) 99:148–154.
- BERG DJ, LEACH MW, KUHN R et al.: Interleukin-10 butnot interleukin-4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med. (1995) 182:99–108.
- BOUILLON R, VERSTUY FA, BRANISTEANU D, WAER M,MATHIEU C: Immune modulation by vitamin D ana-logues in the prevention of autoimmune disease. Verb. K. Acad. Geneeskd. Belg. (1995) 57:371–385.
- SCHILLI MB, PAUS R, CZARNETZKI BM, REICHRATH J:Vitamin D3 and its analogues as multifunctional steroid hormones. A dermatological view of molecular and clinical aspects. Hautarzt (1994) 45:445–452.
- MACDONALD PN, DOWD DR, HAUSSLER MR: New insight Into the structure and functions of the vitamin D recep-tor. Semin. NephroL (1994) 14:101–118.
- CARLBERG C: The concept of multiple vitamin D signal-ing pathways J. Invest. Dermatol. (1996) 1:10–14.
- ICANG S, LI X-Y, VOORHEES JJ: Pharmacology and mo-lecular action of retinoids and vitamin D Laskin. J. Invest. Dermatol. (1996) 1:15–21.
- NORMAN AW: The vitamin D endocrine system: ma-nipulation of structure-function relationship to pro-vide opportunities for development of new cancer chemo preventative and immunosuppressive agents. J. Cell Btochem. (1995) 58\(Suppl. 221:218–225.
- JONES G, CALVERLEY MJ: A dialogue on analogues: newer vitamin D drugs for use in bone disease, psoriasis and cancer. Trends Endocrinol. Metab. (1993) 4:297–303.
- BAADSGAARD 0: Potential mechanism of action of vitamin D and analogues in psoriasis. Acta Derrn. Ven-ereol. (1994) 186:178–182.
- VAN DE KERKHOF PCM: Biological activity of vitamin Danalogues in the skin, with special reference to antip-soriatic mechanisms. Br. J. Dermatol. (1995) 132:675–682.
- MASUDA S, STRUGNELL S, CALVERLEY MJ et al.: In vitrometabolism of anti-psoriatic vitamin D analog, cal-cipotriol, in two cultured human keratinocyte models. J. Biol. Chem. (1994) 269:4794–4803.
- KRAGBALLE K: Calcipotriol: a new drug for topical psoriasis treatment. Pharmacol. Toxicol. (1995) 77:241–246.
- GUMOWSKI SUNEK D, RIZZOLI R, SALTRAT pi: Oral cal-cium tolerance test in extensive psoriasis treated with topical caldpotrioL Dermatology (1995) 190:43–47.
- BOURKE JF, BERTH-JONES J, MUMFORD R, IQBAL HUTCHINSON PE: High dose topical calcipotriol consis-tently reduces serum parathyroid hormone levels. CIO:. Endocrinot (1994) 41:295–297.
- NISHIMURA M, MAKIN° Y, MATUGI H: Tacalcitrol oint-ment for psoriasis. Acta Derm. VenereoL (1994) 186:166–168.
- BAADSGAARD 0, TRAULSEN J, ROED-PETERSEN J, JAKOB-SEN HB: Optimal concentration of tacalcitrol in once daily treatment of psoriasis. J. Dermatol. Treat. (1995) 6:145–150.
- MARTIN BOURRET V, THIVOLET J: Treatment of 15 pso-riatk patients with calcitriol per os. Nouv. Dermatol. (1995) 14:28–33.
- STUTTGEN G: Zur lokal behandlung von keratosen mit vitamin A saure. Dermatologica (1962) 124:65–80.
- LOGAN WS: Vitamin A and keratinisation. Arch. Derma-tol. (1972) 105:748–753.
- PLEWIG GL, KLIGMAN AM: Vitamin A in acneiform der-matoses. Acta Derm. Venereol. (1975) 55:119–127.
- REHTIJARVI K: Vitamin A acid in the local treatment of congenital ichthyosiform erythroderrna. Acta Derrn. Venereol (1975) 55:145–146.
- ALLENBY G, BOCQUEL MT, SAUNDERS M et aL: Retinoic add receptors and retinoid X receptors: interactions with endogenous retinoic acids. Rettnoids Today Tomor-row(1993) 33:23.
- PEDACE J, STOUGHTON R: Topical retinoic acid in acne vulgaris Br. J. Dermatol. (1971) 84:465–469.
- CHALKER DK, LESHER JL, GRAHAM-SMITH J et al.: Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double blind investigation./ Am. Acad. Dermatol. (1987) 17:251–254.
- BRAZZELL RK, VANE FM, EHMANN CW: Pharmacokinet-ics of isotretinoin during repetitive dosing to patients. Eur. J. Ctn. Pharmacol. (1983) 4:695–702.
- GEIGER JM, SAURAT JH: Acetretin and etretinate: how and when they should be used. Dermatol. din. (1993) 11:117–129.
- SHALITA A, WEISS JS, CHALKER DK et aL: A comparison of the efficacy and safety of adapakne gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter triaL J. Am. Acad. Dermatol. (1996) 34:482–485.
- FORD-HUTCHINSON AW: Leukotriene B4 in inflamma-tion. Crit. Rev. Immunol. (1990) 10:1–12.
- FUNK JO, MAIBACH HI: Horizons in pharmacologic Intervention in allergic contact dermatitis. J. Am. Acad. Dermatol. (1994) 31:999–1014.
References to Patent Literature
- LEO PHARM. PRODUCTS LTD. AS, W09319044 (1993).
- LEO PHARM. PRODUCTS LTD. AS, W09401398 (1994).
- LEO PHARM. PRODUCTS LTD. AS, W09407852 (1994).
- LEO PHARM. PRODUCTS LTD. AS, W09407851 (1994).
- LEO PHARM. PRODUCTS LTD. AS, W09410139 (1994).
- LEO PHARM. PRODUCTS LTD. AS, W09502577 (1995).
- LEO PHARM. PRODUCTS LTD. AS, W09414453 (1992).
- JOHNS HOPKINS UNIVERSITY, US5274142 (1993).
- JOHNS HOPKINS UNIVERSITY, US5403832 (1995).
- JOHNS HOPKINS UNIVERSITY, US 5389622 (1995).
- DAIKIN INDUSTRIES LTD., W09316040 (1993).
- DAIKIN INDUSTRIES LTD., US5206230 (1993).
- DAIKIN INDUSTRIES LTD., EP-529528 (1993).
- DAIKIN INDUSTRIES LTD., US5278155 (1994).
- DAIKIN KOGYO KK, JP7304732 (1995).
- DAIKIN KOGYO ICK, JP7304733 (1995).
- LABORATOIRE THERAMEX SA, W09501960 (1995).
- RESEARCH INST. FOR MEDICINE & CHEMISTRY, W09503273 (1995).
- ALLERGAN, INC., W09316029 (1993).
- ALLERGAN, INC., W09316067 (1993).
- ALLERGAN, INC., W09316068 (1993).
- ALLERGAN, INC., W09611686 (1996).
- ALLERGAN, INC., US5348975 (1994).
- ALLERGAN, INC., US5346915 (1994).
- ALLERGAN, INC., US5346895 (1994).
- ALLERGAN, INC., US5344959 (1994).
- ALLERGAN, INC., W09511242 (1995).
- ALLERGAN, INC., W09518803 (1995).
- ALLERGAN, INC., W09518120 (1995).
- ALLERGAN, INC., US5434173 (1995).
- ALLERGAN, INC., US5470999 (1995).
- ALLERGAN, INC., US5391753 (1995).
- ALLERGAN, INC., US5498795 (1996).
- ALLERGAN, INC., US5489584 (1996).
- ALLERGAN, INC., W09606070 (1996).
- UNIVERSITY OF HAWAII, W09221643 (1992).
- L'OREAL, EP-518722 (1992).
- LIGAND PHARM., INC., W09415902 (1994).
- LIGAND PHARM., INC., W09415901 (1994).
- LIGAND PHARM., INC., W09532946 (1995).
- LIGAND PHARM., INC., W09321146 (1993).
- PFIZER, INC., W09306086 (1993).
- BRISTOL-MYERS SQUIBB CO., EP-661259 (1995).
- BRISTOL-MYERS SQUIBB CO., EP-661261 (1995)
- CIBA-GEIGY AG, W09321195 (1993),
- CIBA-GEIGY AG, GB2282596 (1995).
- ALCON LABS., W09610403 (1996).
- EISAI CO. LTD., WP9414777 (1994).
- SRI INT. et al., USS466861 (1995).
- PIERRE FABRE COSMETIQUE, W09306818 (1993).
- ORTHO PHARM. CORP., EP-566405 (1993).
- ORTHO PHARMACEUTICAL CORP., JP100443 (1994).
- YAMANOUCHI EUROPE BY, W09501160 (1995).
- PFIZER, INC., W09315066 (1993).
- PFIZER, INC., W09611920 (1996).
- PFIZER, INC., W09611925 (1996).
- GD SEARLE & CO., W09221644 (1992).
- BOEHRINGER INGELHEIM GMBH et al,W09316036 (1993).
- TEVA PHARM. IND. LTD. etal., EP-544391 (1993).
- YEDA R&D CO. LTD., W09411006 (1994).
- LIGAND PHARM., INC., W09531722 (1995).
- SMITHKLINE BEECHAM CORP., W09513067 (1995).
- RES. DEVELOPMENT FDN., W09518606 (1995).